Log In
BCIQ
Print this Print this
 

PanAd3/MVA RSV vaccine

  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionHeterologous prime boost regimen with vectors encoding a string of RSV proteins F,N and M2-1 bearing both B and T cell epitopes
Molecular Target Not applicable
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine
Latest Stage of DevelopmentPhase I
Standard IndicationRespiratory syncytial virus (RSV)
Indication DetailsPrevent respiratory syncytial virus (RSV)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today